Pharmacokinetics of Meropenem in Patients with Cystic Fibrosis

摘要: The pharmacokinetics of meropenem were studied after single i.v. infusions 15 mg meropenem/kg body weight in eight subjects with cystic fibrosis (CF) and healthy volunteers matched for age, sex, weight. Significantly shorter terminal half-lives (mean, 0.74 h vs. 0.99 h) mean residence times 1.09 1.39 noted CF subjects. Plasma renal clearances tended to be higher distribution volumes smaller among the patients, but differences not statistically significant. results are consistent findings many other beta-lactam agents used patients. Assuming a MIC90 4 mg/l against Pseudomonas aeruginosa, time above MIC was less than 3.3 six This finding should kept mind when designing treatment regimens